C. Michael Gibson, M.S., M.D.

Office Address: Beth Israel Hospital, 330 Brookline Avenue, Boston MA, 02215

Home Address: 1 Carter Drive, Natick MA 01760 (effective Feb 1, 2001)

E:Mail: mgibson@perfuse.org FAX: 415-514-0505 (through Feb 1, 2001)

Place of Birth: Tulsa Oklahoma

Education:

1982 B.A. University of Chicago, Biological Sciences

1984 M.S. University of Chicago, Arts and Sciences Basic to Human Biology and Medicine

1986 M.D. University of Chicago, Pritzker School of Medicine

Postdoctoral Training:

Internships and Residencies:

1986-1987 Intern in Medicine, Brigham and Women's Hospital, Boston MA, Harvard Medical School

1987-1989 Junior and Senior Resident in Medicine, Brigham and Women's Hospital, Boston MA, Harvard Medical School

1989 Chief Medical Resident Physician, West Roxbury Veterans Administration Hospital, Boston MA, Harvard Medical School (During three months as a Senior Resident, Brigham and Women=s Hospital)

1992-1993 Chief Medical Resident Physician, Brigham and Women's Hospital, Boston MA, Harvard Medical School

Clinical and Research Fellowships:

1989-1992 Cardiology Fellow, Beth Israel Hospital, Cardiovascular Division, Boston MA, Harvard Medical School

Academic Appointments:

7/91-4/95 Instructor in Medicine, Harvard Medical School

4/95-6/98 Assistant Professor of Medicine, Harvard Medical School

11/98-8/99 Professor of Medicine, Medical College of Pennsylvania / Hahnemann University School of Medicine

9/99-2/01 Associate Professor of Medicine, University of California San Francisco

Hospital Appointments:

1989- Founder and Director, PERFUSE Core Laboratories and Data Coordinating Center, a non-profit Academic Research Organization (ARO)

1991-1994 Director, Quantitative Angiographic Core Laboratory, Invasive Cardiology Section, Beth Israel Hospital, Harvard Medical School, Boston MA

1993-1994 Director, Coronary Care Unit, Beth Israel Hospital, Harvard Medical School, Boston MA.

1993-1994 Associate in Medicine, Beth Israel Hospital, Harvard Medical School, Boston MA.

1994-1998 Director, Interventional Cardiology, West Roxbury Veteran's Administration Hospital, Harvard Medical School, Boston MA.

1994-1998 Director, Cardiac Catheterization Laboratory, West Roxbury Veteran's Administration Hospital, Harvard Medical School, Boston MA.

1994-1998 Associate Physician, Brigham and Women's Hospital, Harvard Medical School, Boston MA.

1996-1998 Director, Clinical Trials Unit, West Roxbury Veteran=s Administration Hospital, Harvard Medical School, Boston MA.

1996-1998 Chief, Cardiovascular Division, West Roxbury VA Hospital, Harvard Medical School, Boston MA.

1997- Director TIMI Master Database and Coordinating Center

1998-1999 Director of Invasive Cardiology, Allegheny General Hospital

1998-1999 Director Interventional Cardiology Fellowship Program, Allegheny General Hospital

1998-1999 Vice Chairman of Medicine, Clinical Research, Allegheny General Hospital

1999-2000 Associate Chief of Cardiology, University of California San Francisco

1999-2000 Chief, Interventional Cardiology, University of California San Francisco

Feb 2001 Associate in Medicine, Beth Israel Hospital, Harvard Medical School, Boston MA.

Major Committee Assignments:

Hospital:

1992-1993 Intern selection committee, Brigham and Women's Hospital, Boston MA.

1992-1993 Emergency Room Services Committee, Brigham and Women's Hospital, Boston MA

1993-1994 Critical Care Committee, Beth Israel Hospital, Boston MA

1993-1994 Quality Assurance Committee, Beth Israel Hospital, Boston MA

1993-1994 Patient Care Committee, Beth Israel Hospital, Boston MA

1993-1994 Intern selection Committee, Beth Israel Hospital, Boston MA

1996 Massachusetts Peer Review Organization (MASS PRO) reviewer of acute myocardial infarction processes and outcomes at academic institutions in the Boston area

1995-1997 Director Cardiovascular Grand Rounds, West Roxbury Veterans Administration Hospital

1997 Conscious sedation committee, West Roxbury Veterans Administration Hospital

1997 Chairman, Coronary Intermediate Care Unit and Outpatient Cardiac Catheterization Activation Committee, West Roxbury Veterans Administration Hospital

1998-1999 Chairman, Cardiac Catheterization Laboratory Resource Utilization Committee, Allegheny General Hospital

1998-1999 Chairman, Cardiac Catheterization Laboratory Executive Committee, Allegheny General Hospital

1998-1999 Directed committee dedicated to improving Clinical Research at Allegheny General Hospital:

1. Conceived and developed a database for tracking the time it takes for trials to be approved: (time for grants & contracts office to prepare trial budget; time for Principal Investigator to submit to IRB; time from submission to IRB to first review; time for PI to resubmit protocol to IRB for re-review; time for IRB to review protocol again; time for PI to submit all required changes; total time for IRB approval; time for legal review; time required for sponsor to sign off on contract; time for administrative sign off; time for Department/Division sign off. As a result of all of the above, reduced time required for trials to be enrolling by one month.

2. Conceived and edited Department of Medicine Newsletter regarding 38 ongoing Clinical Trials: Changes in operational policies disseminated; dates and times of educational programs posted; publications of investigators listed; new trial every month highlighted; active trials with contact numbers listed.

3. Renegotiated cost structure of clinical trials accounting system for entire hospital system from one that used highly volatile cost-to-charge ratios to one that used unvarying Medicare costs and stabilized cost accounting system. Conceived and directed creation of 300 page master list of costs for all tests in hospital that was accessible to clinical researchers.

4. Conceived and directed SCORE program (Scholars Concentrating On Research Excellence), a 16 lecture educational program directed at research coordinators, residents, fellows, and attending physicians designed to educate clinical researchers. Each participant received a 200 page binder of curricular materials. Topics included: trial design; statistical methodology (power, sample size, confidence intervals); site readiness; regulatory issues (IRB, adverse event reporting); good clinical practices; clinical event committees, data safety monitoring; database management; statistical analysis software, including a “how to manual”; techniques in the assessment of cost effectiveness, quality of life, patient satisfaction; trial management (CRO, Chairman’s office, Core Lab); the FDA approval process.

5. Conceived and directed development of software to track clinical trials monies. Designed budget sheet which tracked % of monies spent on patient care and compared this with trial projections to assure that hospital was being reimbursed appropriately for services and test; tracked number of patients enrolled and projections of monies owed by sponsors; developed warning systems to identify investigators who were over budget. Realized net profit of $172,000.00 in 9 months (annualized profit of $230,000.00) on revenues of $351,000.00 (annualized revenues of $468,000.00).

1999-2001 Quality Assurance Committee, Cardiac Catheterization Laboratory, University of California San Francisco

Academic:

1994-1995 Member TIMI 9B Morbidity and Mortality Classification Committee

1995-1998 Chairman, Data Safety Monitoring Board for a trial assessing Transmyocardial Laser Revascularization in inoperable coronary artery disease.

1996 Member TIMI 11A Morbidity and Mortality Classification Committee

1996 Ad Hoc Member NHLBI Clinical Trials Review Committee

1996-1998 Chairman, Data Safety Monitoring Board for a trial assessing Transmyocardial Laser Revascularization as an adjunct to Coronary Artery Bypass Grafting

1997- Director Master Database for the TIMI Studies

Professional Societies:

1986 Member American Medical Association

1992 Fellow American College of Angiology

1996 Fellow American College of Cardiology

2000 Member California Academy of Medicine

Editorial Boards and Manuscript Review:

Journals

Editorial Board, Journal of Thrombosis and Thrombolysis

Reviewer, Circulation, American Heart Association

Reviewer, Journal American College of Cardiology

Reviewer, American Journal of Cardiology

Reviewer, American Heart Journal

Reviewer, Cardiac Catheterization and Diagnosis

Internet Publications / Websites

Editorial Board www.theheart.org

Associate Editor, www.chestpainonline.org

Founder and Editor-in-Chief of www.clinicaltrialresults.org an online resource for the distribution of clinical trial results. Creator and Webmaster of the site.

Founder and Editor-in-Chief of www.perfuse.org, a website dedicated to the distribution of information regarding the analysis of coronary blood flow

Creator, editor and webmaster of the www.timi.org, a website dedicated to the distribution of information regarding the outcomes of trials in the area of acute coronary syndromes

Awards and Honors:

High School

1978 Ranked first among 225 recipients of a National Honor Society scholarship from a national applicant field of 36,000 students by the combined committees of the National Honor Society, Educational Testing Service and the Secondary School Principal's Association.

Class Valedictorian

Four sport varsity letterman.

Special National Merit Scholar

College

1982 graduated Phi Beta Kappa

1982 Graduated with General and Special Honors as an undergraduate student

Associate membership in Sigma Xi Research Society

Three year varsity letterman in football. Starting halfback second year of college

Rhodes scholarship state finalist

Dean's List for 4 years

Medical School

1984 National Young Investigator Award in Orthopedic Surgery

1986 Graduated Alpha Omega Alpha

1986 Honors graduate, Pritzker School of Medicine University of Chicago

Post Graduate

1993-1994 Julian and Eunice Cohen Scholar in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston MA

Part II: Research, Teaching, and Clinical Contributions

Narrative report of Research, Teaching, and Clinical Contributions

Dr. Gibson is founder and director of PERFUSE (Percutaneous/Pharmacologic Endoluminal Revascularization For Unstable Syndromes Evaluation), an academic research organization. Dr. Gibson’s work has largely focused on the development of the statistical and angiographic methodologies to investigate the pathophysiology of coronary artery disease and the efficacy of therapeutic modalities. He directs the Angiographic Core Laboratory for a wide variety of studies including acute MI studies, large scale international interventional trials, numerous new device trials, peripheral interventional trials, angiogenesis trials (VEGF), imaging modality studies, managed care analyses for HCFA, and atherosclerosis regression trials such as the NIH-sponsored Harvard Atherosclerosis Reversibility Project (HARP) and PEARL (role of estrogens in restenosis).

In the field of atherosclerosis, Dr. Gibson determined that the multiple blockages within a patient progress in their severity at independent rates, and he along with Dr. Bernard Rosner developed and validated the statistical methodology that is used to analyze angiographic data from many atherosclerosis regression trials. Likewise, in the field of interventional cardiology, Dr. Gibson demonstrated that when multiple blockages within a patient are dilated, the risk of reblockage or restenosis is independent among all the lesions. This provides the methodological basis for all interventional trials analyzing restenosis data on a per lesion basis rather than on a per patient basis.

Dr. Gibson developed the TIMI (Thrombolysis In Myocardial Infarction) frame count (CTFC) in which the number of cineframes for dye to reach standardized distal landmarks is counted as an index of coronary blood flow. This measure is now the primary endpoint in some acute MI trials. Dr. Gibson also developed the TIMI myocardial perfusion grade (a measure of microvascular perfusion). In this method, the rate of dye entry and exit from the heart muscle is assessed visually. The TIMI frame count and the TIMI myocardial perfusion grade are both multivariate predictors of mortality in acute MI. The thrust of Dr. Gibson’s current research lies in developing computer techniques to more precisely quantitate the flow of dye into the heart muscle to quantitate the perfusion of the myocardium at the microvascular or tissue level.

The TIMI study group has 15 years in the conduct of trials in acute coronary syndromes. Over the past 3 years Dr. Gibson has coordinated substudy queries from TIMI trials 1 to 14. Dr. Gibson directed the creation of a master database that unifies data from multiple TIMI trials.

Dr. Gibson is an active interventional cardiologist and has served as Chief of Interventional Cardiology in several catheterization laboratories (West Roxbury VA, Allegheny General, University California San Francisco) and has served as Director of the Coronary Care Unit at Beth Israel Hospital. He has been active as an administrator (Chief of Cardiology West Roxbury VA, Vice Chairman of Medicine Allegheny General Hospital, Associate Chief of Cardiology University California San Francisco) and has been active in overseeing the education of trainees (Chief Resident Brigham and Women’s Hospital, Cardiology Fellowship Director Allegheny General Hospital).

Research Funding Information:

Past:

1988-93 National Institute of Health, Director of Quantitative Angiographic Core Laboratory Harvard Atherosclerosis Reversibility Project, Lipid Lowering Trial

1988-93 National Institute of Health, Director of Quantitative Angiographic Core Laboratory Harvard Atherosclerosis Reversibility Project, Fish Oil Trial

1991-93 Smith Kline Beecham, Thrombolysis in Myocardial Infarction Phase 4 (TIMI 4) Director of Quantitative Angiographic Core Laboratory for TIMI 4

1993-94 Ciba Geigy, Principal Investigator, Beth Israel Hospital, Harvard Medical School, Thrombolysis in Myocardial Infarction Phase 9A (TIMI 9A)

1993-94 Ciba Geigy, Director of the Quantitative Angiographic Core Laboratory for the Thrombolysis In Myocardial Infarction Phase 9A trial (TIMI 9A)

1993-94 Biogen Inc., Principal Investigator, Beth Israel Hospital and subsequently West Roxbury Veteran's Administration, Harvard Medical School, of a prospective randomized trial comparing the efficacy of hirulog versus heparin in preventing post PTCA reocclusion

1993-94 Otsuka Pharmaceutical, Principal Investigator of a randomized trial comparing the efficacy of Vesniranone to Dobutamine, Beth Israel Hospital, Harvard Medical School

1993-94 Merck Dupont, Principal Investigator, Beth Israel Hospital, Harvard Medical School, Coumadin Aspirin Reinfarction Study (CARS)

1993-94 Biogen Inc., Principal Investigator, Beth Israel Hospital, Harvard Medical School, Hirulog in the Treatment of Heparin Associated Thrombocytopenia

1994-95 Health Care Finance Administration, (HCFA), Director, Quantitative Angiographic Core Laboratory, West Roxbury Veteran's Administration, Harvard Medical School, for the Comparative Analysis of Disease Extent Prior to Coronary Artery Bypass Grafting, West Roxbury Veteran's Administration Hospital, Boston MA

1995-96 Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, Thrombolysis In Myocardial Infarction Phase 11 trial (TIMI 11A) of Enoxaperin

1995-97 Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, TIMI 12, a phase 2 Trial of Ro 48-3657 (a new oral IIb/IIIa platelet receptor antagonist)

1995-97 Director of the Quantitative Angiographic Core Laboratory for the Thrombolysis In Myocardial Infarction Phase 10 pilot trial (TIMI 10A), West Roxbury Veteran's Administration Hospital, Harvard Medical School, Boston MA

1995-97 Co-Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, MK-383 in the Treatment of Unstable Angina

1995-97 Principal Investigator of the quantitative angiographic analysis of the International 2,100 patient MK-383 restenosis trial in patients undergoing conventional PTCA or Atherectomy (RESTORE)

1995-97 Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, MK-383 in Patients Undergoing Conventional PTCA or Atherectomy

1995-97 Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, Veterans Administration Cooperative Trial Comparing Coronary Artery Bypass Grafting to PTCA in patients with Unstable Angina (AWESOME)

1995-97 Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, NIH-sponsored Triggers of acute MI study

1995-97 Director, Angiographic and Electrocardiographic Core Laboratory for comparative evaluation of the FreeFlow catheter, Schneider Inc.

1996-98 Principal Investigator of the quantitative angiographic analysis of the DVI medium sized vessel atherectomy trial

1996-98 Director of the quantitative angiographic analysis of the Thrombolysis In Myocardial Infarction Phase 10 B trial of TNK

1996-98 Principal Investigator West Roxbury VA Hospital, AVERT trial of Atorvastatin

1996-98 Principal Investigator of the quantitative angiographic analysis of the WALLSTENT Femoral Endoprosthesis and the Unistep Plus Delivery System

1996-98 Principal Investigator of the quantitative angiographic analysis of the WALLGRAFT Endoprosthesis with PET Covering and the Unistep LS Delivery System

1997-98 Principal Investigator, West Roxbury Veterans Administration Hospital, TIMI 11B Trial of Enoxaperin

1997 Principal Investigator of the quantitative angiographic analysis of the ANGIOSTENT Trial

1997-98 Principal Investigator of the angiographic core laboratory for the phase 1B trial of rh-VEGF

1997-98 Principal Investigator, West Roxbury Veterans Administration Hospital, ProntoFlex Perfusion balloon Trial

1998 Principal Investigator of the BARD study of geometry of bifurcation lesions

1998-99 Principal Investigator of the quantitative angiographic analysis, data entry and management, of the angiographic core laboratory for an International Multicenter 350 patient phase II trial of Vasoflux, sponsored by Vascular Therapeutics Inc. (The VITAL Trial)

1998-99 Principal Investigator of the quantitative angiographic analysis, data entry and management, of the angiographic core laboratory for a Phase III, Multicenter, Single Blind Study Comparing Non-Enhanced Stress Echocardiography in the Visualization of Wall Motion and the Diagnosis of Coronary Artery Disease (ECHOGEN trial)

1998-00 Principal Investigator of the quantitative angiographic analysis, data entry and management, of the angiographic core laboratory for the Thrombolysis In Myocardial Infarction Phase 14 trial (TIMI 14) of ReoPro in acute MI

1998-00 Principal Investigator rendering the final readings for the pooled data from the SPEED and TIMI 14 trials of ReoPro plus RPA in acute MI

Current

1998- Principal Investigator of the quantitative angiographic analysis, data entry and management, of the angiographic core laboratory for the TIMI 18 TACTICS trial

1998- Principal Investigator of the quantitative angiographic analysis, data entry and management, of the angiographic core laboratory for the LIMIT trial of rhuMAb CD18 as an adjunct to thrombolysis (an antibody directed against neutrophils)

1998- Principal Investigator of the angiographic core laboratory for the phase 2 trial of rh-VEGF

2000- Principal Investigator of the quantitative angiographic analysis of the ESPRIT trial

2000- Principal Investigator of the quantitative angiographic analysis of the NIH-sponsored PEARL study of estrogens in restenosis

1999- Principal Investigator quantitative angiographic analysis, data entry and management of angiographic data from an international multicenter trial entitled An open study, with blinded endpoint assessment, to assess the safety, tolerability and the effect on coronary artery patency of intravenous AR-C69931MX as both monotherapy and adjunct to Activase in patients with ST-elevation myocardial infarction (the STEP AMI trial)

1999- Principal Investigator quantitative angiographic analysis, data entry and management of angiographic data from an international multicenter trial of tirofiban plus low dose TNK in patients with ST-elevation myocardial infarction (FASTER trial)

1999- Principal Investigator quantitative angiographic analysis, data entry and management of angiographic data from an international multicenter trial of Enoxaperin plus low dose TNK in patients with ST-elevation myocardial infarction (the ENTIRE trial)

1999- Principal Investigator quantitative angiographic analysis, data entry and management of angiographic data from an international multicenter trial of eptifibatide plus low dose TNK in patients with ST-elevation myocardial infarction (the INTEGRITI trial)

1996- Principal Investigator of the quantitative angiographic analysis of the Schneider Wallstent in peripheral vessels

1996- Principal Investigator of the quantitative angiographic analysis of the Schneider Wallstent in central vessels

Major Research Interests:

Founder and Director of the PERFUSE Core Laboratories and Data Coordinating Center

(Percutaneous/Pharmacologic Endoluminal Revascularization For Unstable Syndromes Evaluation)

1. Atherosclerosis Regression and Prevention

Director of the quantitative angiographic analysis of the NIH sponsored Harvard Atherosclerosis Reversibility Project (HARP) Lipid Lowering Trial

Director of the quantitative angiographic analysis of the NIH sponsored Harvard Atherosclerosis Reversibility Project (HARP) Fish Oil Trial

Principal Investigator West Roxbury VA Hospital, Harvard Medical School, AVERT trial of Atorvastatin versus PTCA

2. Thrombolysis and Unstable Angina

Director of the quantitative angiographic analysis of the Thrombolysis In Myocardial Infarction Phase 4 trial (TIMI 4)

Director of the quantitative angiographic analysis of the Thrombolysis In Myocardial Infarction Phase 9A trial (TIMI 9A)

Principal Investigator, Beth Israel Hospital, Thrombolysis in Myocardial Infarction Phase 9A (TIMI 9A)

Member TIMI 9B Morbidity and Mortality Classification Committee

Director of the quantitative angiographic analysis of the Thrombolysis In Myocardial Infarction Phase 10 pilot trial (TIMI 10A)

Director of the quantitative angiographic analysis of the Thrombolysis In Myocardial Infarction Phase 10 B trial (TIMI 10B) of TNK

Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, TIMI 11A Trial of Enoxaperin

Member TIMI 11A Morbidity and Mortality Classification Committee

Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, TIMI 11B Trial of Enoxaperin

Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, TIMI 12A, a phase 2 Trial of Ro 48-3657 (a new oral IIb/IIIa platelet receptor antagonist)

Principal Investigator, Beth Israel Hospital, Harvard Medical School, Coumadin Aspirin Reinfarction Study (CARS)

Collaborated as the Angiographic Core Laboratory for the Coumadin Aspirin Reinfarction Study (CARS)

Principal Investigator, Beth Israel Hospital, Harvard Medical School, Hirulog in the Treatment of Heparin Associated Thrombocytopenia

Co-Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, MK-383 in the Treatment of Unstable Angina

Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, NIH- sponsored Triggers of acute MI study

Director of the quantitative angiographic analysis of the Thrombolysis In Myocardial Infarction Phase 14A trial (TIMI 14) of ReoPro in acute MI

Principal Investigator of the angiographic core laboratory for an International Multicenter 350 patient phase II trial of Vasoflux (VITAL)

Principal Investigator of the angiographic core laboratory for the LIMIT trial, an international multicenter 500 patient trial of rhuMAb CD18 as an adjunct to thrombolysis (an antibody directed against neutrophils)

Principal Investigator of the angiographic core laboratory for an international multicenter trial of low dose RPA plus full dose ReoPro in acute MI (SPEED Trial: Strategies for Patency Enhancement in the Emergency Department). Rendered final angiographic core laboratory readings on data to be pooled with the TIMI 14 trial.

Principal Investigator of the angiographic core laboratory for an international multicenter trial entitled An open study, with blinded endpoint assessment, to assess the safety, tolerability and the effect on coronary artery patency of intravenous AR-C69931MX as both monotherapy and adjunct to Activase in patients with ST-elevation myocardial infarction (STEP AMI)

Principal Investigator of the angiographic core laboratory for an international multicenter trial of tirofiban plus low dose TNK in patients with ST-elevation myocardial infarction (FASTER trial)

Principal Investigator of the angiographic core laboratory for an international multicenter trial of Enoxaperin plus low dose TNK in patients with ST-elevation myocardial infarction (the ENTIRE trial)

Principal Investigator of the angiographic core laboratory for an international multicenter trial of eptifibatide plus low dose TNK in patients with ST-elevation myocardial infarction (the INTEGRITI trial)

3. Interventional Cardiology

Principal Investigator of the Angiographic Core Laboratory for the International 2,100 patient MK-383 restenosis trial in patients undergoing conventional PTCA or Atherectomy (RESTORE)

Principal Investigator, Beth Israel Hospital and West Roxbury Veterans Administration Hospital, Harvard Medical School, of a prospective randomized trial comparing the efficacy of hirulog versus heparin in preventing post PTCA reocclusion

Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, MK-383 in Patients Undergoing Conventional PTCA or Atherectomy (RESTORE)

Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, Veterans Administration Cooperative Trial Comparing Coronary Artery Bypass Grafting to PTCA in patients with Unstable Angina (AWESOME trial)

Principal Investigator of the quantitative angiographic analysis for a comparative evaluation of the Free Flow catheter (Schneider Inc.)

Principal Investigator of the quantitative angiographic analysis of the DVI intermediate sized vessel atherectomy trial (IVAT)

Principal Investigator of the quantitative angiographic analysis of the Schneider WALLSTENT in peripheral vessels

Principal Investigator of the quantitative angiographic analysis of the Schneider WALLSTENT in central vessels

Principal Investigator of the quantitative angiographic analysis of the WALLSTENT Femoral Endoprosthesis and the Unistep Plus Delivery System

Principal Investigator of the quantitative angiographic analysis of WALLGRAFT

Endoprosthesis with PET Covering and the Unistep LS Delivery System

Principal Investigator, West Roxbury Veterans Administration Hospital, Harvard Medical School, ProntoFlex Perfusion balloon Trial

Principal Investigator of the quantitative angiographic analysis of the

ANGIOSTENT Trial

Principal Investigator of the quantitative angiographic analysis of the TACTICS-TIMI 18 trial comparing conservative versus interventional strategies in patients with UA/NQWMI

Principal Investigator of the BARD study of geometry of bifurcation lesions

Principal Investigator of the quantitative angiographic analysis of the ESPRIT trial

Principal Investigator of the quantitative angiographic analysis of the NIH-sponsored PEARL study of estrogens in restenosis

Principal Investigator of the quantitative angiographic analysis of the Percusurge device

Principal Investigator of the quantitative angiographic analysis of a study to examine the predictors of subacute stent thrombosis

4. Angiogenesis

Principal Investigator of the angiographic core laboratory for the phase 1B trial of rh-VEGF

Principal Investigator of the angiographic core laboratory for the phase 2 trial of rh-VEGF

Selected as Principal Investigator of the angiographic core laboratory for 3 upcoming phase 1 and 2 trials of VEGF

5. Congestive Heart Failure

Principal Investigator, Beth Israel Hospital, Harvard Medical School, of a randomized trial comparing the efficacy of Vesniranone to Dobutamine

6. Quantitative Angiography

Director, Quantitative Angiographic Core Laboratory, West Roxbury Veteran's Administration, Harvard Medical School, for the Comparative Analysis of Disease Extent Prior to Coronary Artery Bypass Grafting, sponsored by the Health Care Finance Administration, (HCFA)

Director, Quantitative Angiographic Core Laboratory, Phase II Feasibility Study of the Safety and Efficacy of Coronary Magnetic Resonance Angiographic (CMRA) Imaging with MS-325 (a comparison of MRI and angiography)

Director, Quantitative Angiographic Core Laboratory, Phase III, Multicenter, Single Blind Study Comparing Non-Enhanced versus enhanced Stress Echocardiography in the Visualization of Wall Motion and the Diagnosis of Coronary Artery Disease (the ECHOGEN trial)

7. Electrocardiography:

Principal Investigator of the electrocardiographic core laboratory for the Schneider FreeFlowTM perfusion balloon trial

Directed EKG analysis and substudies from TIMI 10A

Directed EKG analysis and substudies from TIMI 10B

8. Data Coordination:

Direct acquisition and coordination of all cleaned data from clinical research organizations as it pertains to the following TIMI Studies (Thrombolysis In Myocardial Infarction) performed to date:

TIMI 1: Thrombolytic therapy with tPA vs SK

TIMI 3A: Thrombolytic therapy versus placebo on lesion severity in unstable angina/non-Q wave MI

TIMI 3B: 1. Thrombolytic therapy versus placebo therapy in unstable angina/non-Q wave MI

2. Early invasive versus early conservative strategy in unstable angina/non-Q wave MI

TIMI 3 Registry: Clinical profile and outcomes of 3,316 patients with unstable angina and non-Q wave MI

TIMI 4: 382 patient trial of tPA versus APSAC versus Combination therapy in Acute MI

TIMI 5: 246 patient trial of Hirudin versus Heparin in Acute MI

TIMI 6: 193 patient trial of Hirudin with Streptokinase in Acute MI

TIMI 7: 410 patient trial of Hirulog in Unstable Angina

TIMI 8: Hirulog versus Heparin in Unstable Angina and Non-Q Wave MI

TIMI 9A: Hirudin versus Heparin with Thrombolysis in Acute MI

TIMI 9B: 3000 patient trial of Hirudin versus Heparin with Thrombolysis in Acute MI

TIMI 10A: 113 patient Dose Escalation Study of TNK-tPA

TIMI 10B: 880 patient trial of TNK-tPA versus front loaded tPA in Acute MI

TIMI 11A: Enoxaperin in Unstable Angina

TIMI 11B: Enoxaperin in Unstable Angina

TIMI 12: TIMI 12, a phase 2 Trial of Ro 48-3657 (oral IIb/IIIa platelet receptor antagonist)

TIMI 14: ReoPro alone versus ReoPro + tPA versus tPA alone versus ReoPro + SK in Acute MI

TIMI 18: (TACTICS) Comparison of conservative versus interventional strategies in patients with UA/NQWMI

Assist in the data coordination and perform data analysis for the trials of Transmyocardial Laser Revascularization (TMR)(PLC Inc.)

TMR vs Medical Management Trial

Data entry, management and analysis of angiographic data from the following interventional trials

Data entry and management of angiographic data for the international RESTORE study of 2,100 patients

Data entry and management of angiographic data for the FreeFlow catheter trial (Schneider Inc.)

Data entry and management of angiographic data for the DVI intermediate sized vessel atherectomy trial (IVAT)

Data entry and management of angiographic data for the Schneider WALLSTENT in peripheral vessels

Data entry and management of angiographic data for the Schneider WALLSTENT in central vessels

Data entry and management of angiographic data for the WALLSTENT Femoral Endoprosthesis and the Unistep Plus Delivery System

Data entry and management of angiographic data for the WALLGRAFT

Endoprosthesis with PET Covering and the Unistep LS Delivery System

Data entry and management of angiographic data for the ANGIOSTENT Trial

Data entry and management of angiographic data for the TACTICS-TIMI 18 trial

Data entry and management of angiographic data of the quantitative angiographic analysis of the Percusurge device

Data entry and management of angiographic data of the quantitative angiographic analysis of a study to examine the predictors of subacute stent thrombosis

Data entry and management of angiographic data from the following thrombolytic trials:

Data entry and management of angiographic data from TIMI 10A and TIMI 10B trials of TNK in Acute MI

Data entry and management of angiographic data from TIMI 14, a trial of ReoPro alone versus ReoPro + tPA versus tPA alone versus ReoPro + SK in Acute MI

Data entry and management of angiographic data from an International Multicenter 350 patient phase II trial of Vasoflux (an antithrombin), sponsored by Vascular Therapeutics Inc. (The VITAL trial)

Data entry and management of angiographic data from the trial of rhuMAb CD18 as an adjunct to thrombolysis (an antibody directed against neutrophils)

Data entry and management of angiographic data from the international multicenter trial of low dose RPA plus full dose ReoPro in acute MI (SPEED Trial: Strategies for Patency Enhancement in the Emergency Department). Rendered final angiographic core laboratory readings on data to be pooled with the TIMI 14 trial.

Data entry and management of angiographic data from an international multicenter trial entitled An open study, with blinded endpoint assessment, to assess the safety, tolerability and the effect on coronary artery patency of intravenous AR-C69931MX as both monotherapy and adjunct to Activase in patients with ST-elevation myocardial infarction (STEP AMI)

Data entry and management of angiographic data from an international multicenter trial of tirofiban plus low dose TNK in patients with ST-elevation myocardial infarction (TNT trial)

Data entry and management of angiographic data from an international multicenter trial of Enoxaperin plus low dose TNK in patients with ST-elevation myocardial infarction (the ENTIRE trial)

Data entry and management of angiographic data from an international multicenter trial of eptifibatide plus low dose TNK in patients with ST-elevation myocardial infarction

9. Transmyocardial and Percutaneous Laser Revascularization

Protocol development, case report design, analysis of outcomes, drug dosing and nuclear data in TMR trials

Chairman, Data Safety Monitoring Board for a trial assessing Transmyocardial Laser Revascularization in inoperable coronary artery disease

Chairman, Data Safety Monitoring Board for a trial assessing Transmyocardial Laser Revascularization as an adjunct to Coronary Artery Bypass Grafting

10. Animal laboratory research

Schneider FreeFlowTM Perfusion Balloon evaluation

Schneider WallstentTM studies

Assessment of a percutaneous myocardial revascularization (PMR) CO2 laser with PLC Inc.

Report of Teaching

Local Contributions

University of Chicago

1981 Teaching Assistant, Division of Biological Sciences, University of Chicago

Harvard Medical School

1989 Responsible for providing lectures biweekly to Harvard Medical Students as Chief Medical Resident at the West Roxbury Veterans Administration Hospital

1992-1993 Responsible for providing lectures biweekly to Harvard Medical Students as Chief Medical Resident at the Brigham and Women=s Hospital

1993-1994 Acute Cardiac Care Elective, Course Director, Harvard medical School (course # ME502M.1b)

1995: Human systems course, section on cardiac imaging, Harvard Medical School

1998-1999: Conceived and directed SCORE program (Scholars Concentrating On Research Excellence), a 16 lecture educational program directed at research coordinators, residents, fellows, and attending physicians designed to educate clinical researchers. Each participant received a 200 page binder of curricular materials. Topics included: trial design; statistical methodology (power, sample size, confidence intervals); site readiness; regulatory issues (IRB, adverse event reporting); good clinical practices; clinical event committees, data safety monitoring; database management; statistical analysis software, including a “how to manual”; techniques in the assessment of cost effectiveness, quality of life, patient satisfaction; trial management (CRO, Chairman’s office, Core Lab); the FDA approval process.

Regional, National, and International Contributions

1993-1994 Medical or Cardiology Grand Rounds at 7 hospitals, Chaired 5th International Symposium on Coronary Arteriography, Session on Regression/Progression of Atherosclerotic Disease, Rotterdam

1995 Invited lectures (Medical or Cardiology Grand Rounds, Symposia) at 10 hospitals, Chaired the "Meet the Experts session on Quantitative Angiography", American College of Cardiology 1995

1996 Invited lectures (Medical or Cardiology Grand Rounds, Symposia) at 18 hospitals or meetings

1997 Invited lectures (Medical or Cardiology Grand Rounds, Symposia) at 22 hospitals or meetings, Directed National Symposium on Intervention in Acute Coronary Syndromes

1998 Chairman of AHA How to Session on the TIMI Frame Count, Invited lectures (Medical or Cardiology Grand Rounds, Symposia) at 20 hospitals or meetings

1999 Invited Lectures (Medical or Cardiology Grand Rounds, Symposia) at 15 hospitals or meetings

Scientific Sessions Chaired

1. 5th International Symposium on Coronary Arteriography, Session on Regression/Progression of Atherosclerotic Disease, Rotterdam June 28-30, 1993.

2.Meet the Experts session on Quantitative Angiography, American College of Cardiology 1995.

3. Intervention in Acute Coronary Syndromes, Allegheny University of the Health Sciences, June 21 and June 22 1997.

4. AHA How to Session on the TIMI Frame Count, 1998.

5. Co chaired “Biotechnology in Cardiovascular Medicine Current and Future Innovations” with Douglas Weaver, AHA satellite symposium 1998.

6. Co chair of “Biotechnology in Cardiovascular Medicine Current and Future Innovations” with Douglas Weaver, AHA satellite symposium 1999.

7. Co chair of “Biotechnology in Cardiovascular Medicine Current and Future Innovations” with Douglas Weaver, AHA satellite symposium 2000.

8. Chairman of AHA How to Symposium on the assessment of the coronary microvasculature, 2000

Report of Clinical Activities

1993-1994 Attending Physician, Coronary Care Unit, Beth Israel Hospital, Harvard Medical School, Boston MA

1993-1994 Attending Physician, Interventional Cardiology Service, Beth Israel Hospital, Harvard Medical School, Boston MA

1993-1994 Attending Physician, Cardiac Catheterization Laboratory, Beth Israel Hospital, Harvard Medical School, Boston MA

1994-1998 Attending Physician, Cardiac Catheterization Laboratory, West Roxbury Veteran's Administration Hospital, Harvard Medical School, Boston MA

1994-1998 Attending Physician, Cardiac Catheterization Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston MA

1998-1999 Attending Physician, Allegheny General Hospital

1999-2001 Attending Physician, University of California San Francisco School of Medicine, Moffitt Hospital

2001- Attending Physician, Interventional Cardiology Service, Beth Israel Hospital, Harvard Medical School, Boston MA

Part III: Bibliography

Original Articles

1. Gibson CM, Gurney CW, Simmons EL, Gaston EO. Cyclic erythropoiesis in the Sl/Sld mouse. Experimental Hematology 1984; 12:343-348.

2. Gibson CM, Gurney CW, Simmons EL, Gaston EO. Further studies of cyclic erythropoiesis in mice. Experimental Hematology 1985; 13:855-860.

3. Gibson CM, Reider B, Mikosz R, Andriacchi T. Analysis of the Mueller anterolateral femorotibial ligament (ALFTL) reconstruction using a computerized knee model. American Journal of Sports Medicine 1985; 14:371-375. (Winner Young Investigator Award)

4. Ridker P, Gibson CM. Atrial fibrillation induced by breath spray (letter). N Eng J Med 1989; 320:124.

5. Gibson CM, Sandor T, Stone PH, Pasternak RC, Rosner B, Sacks FM. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. American Journal of Cardiology 1992; 69:1286-1290.

6. Carrozza JP, Kuntz RE, Levine MJ, Pomerantz RM, Fishman RF, Mansour M, Gibson CM, Senerchia CC, Diver DD, Safian RD, Baim DS. Angiographic and clinical outcome of intracoronary stenting: Acute and long-term results from a large single-center experience. Journal American College of Cardiology 1992; 20:328-337.

7. Stone PH, Gibson CM, Diaz L, Pasternak RC, Sandor T, Rosner B, Sacks FM. The natural history of coronary atherosclerosis using quantitative angiography: Implications for clinical trials of coronary regression. American Journal of Cardiology 1993; 71:766-772.

8. Gibson CM, Diaz L, Kandarpa K, Sacks FM, Pasternak RC, Sandor T, Feldman C, Stone PH. The relationship of vessel wall shear stress to atherosclerosis progression. Arteriosclerosis and Thrombosis 1993; 13:310-315.

9. Kuntz RE, Gibson CM, Nobuyoshi S, Baim DS. A generalized model of restenosis following conventional angioplasty, stenting and directional atherectomy. Journal American College of Cardiology 1993; 21:15-25.

10. Gibson CM, Kuntz RE, Nobuyoshi M, Rosner B, Baim DS. Lesion-to-lesion independence of restenosis following treatment by conventional angioplasty, stenting, or directional atherectomy: Validation for lesion-based restenosis analysis. Circulation 1993; 87:1123-1129.

11. Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilation within coronary stents: A quantitative angiographic assessment. Journal American College of Cardiology 1993; 21:1166-74.

12. Gordon PC, Friederich SP, Piana RN, Kugelmass AD, Leidig GA, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Is 40-70% diameter narrowing at the site of previous stenting or directional coronary atherectomy clinically significant? American Journal of Cardiology 1994; 74:26-32.

13. Ahmed WH, Shubrooks SJ, Gibson CM, Baim DS, Bittl JA. Complications and long-term outcome after percutaneous coronary angioplasty in chronic hemodialysis patients. American Heart Journal 1994; 128:252-5.

14. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP, Kuntz RE, Baim DS. The incidence and treatment of "no-reflow" following percutaneous coronary intervention. Circulation 1994; 89:2514-2518.

15. Antman EM for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the TIMI 9A trial. Circulation 1994; 90:1624-1630. (CM Gibson listed in appendix as a participant of the study group)

16. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri S, Davis V, Gibson CM, Poole WK, Braunwald E & THE TIMI 4 INVESTIGATORS. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. Journal American College Cardiology 1994; 24:1602-10.

17. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. The effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet 1994; 344:1182-1186.

18. Kloner RA, Shook TS, Przyklenk K, Davis V, Junio L, Mathews RV, Burstein S, Gibson CM, Poole K, Cannon CP, McCabe C, Braunwald E for the TIMI 4 Investigators. Previous angina alters in hospital outcome in TIMI 4: A clinical correlate to preconditioning? Circulation 1995; 91:37-47.

19. Zahger D, Cercek B, Cannon CP, Jordan M, Davis V, Braunwald E, Shah PK for the TIMI 4 Investigators. How do smokers differ from nonsmokers in their response to thrombolysis? The TIMI 4 Trial. American Journal Cardiology 1995; 75:232-236.

20. Gibson CM, Cannon CP, Piana RN, Breall JA, Sharaf B, Flatley M, Alexander B, Diver DJ, McCabe CM, Flaker GC, Baim DS, Braunwald E. Angiographic predictors of early reocclusion in the TIMI 4 trial. Journal American College Cardiology 1995; 25:582-589.

21. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable angina or postinfarction angina. N Eng J Med 1995;333:764-9. (CM Gibson listed in appendix as a participant of the study group)

22. Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH for the Harvard Atherosclerosis Reversibility Project (HARP) Research Group. The influence of pre-treatment LDL-cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. American Journal of Cardiology 1995; 76:78C-85C.

23. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. The effect on coronary atherosclerosis of fish oil therapy in patients with normal plasma cholesterol levels. Journal American College Cardiology 1995; 25:1492-8.

24. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. The TIMI Frame Count: A Quantitative Method of Assessing Coronary Artery Flow. Circulation, 1996; 93:879-888.

25. Kloner RA, Gibson CM, Cannon CP, Braunwald E. Preinfarction angina (letter). N Eng J Med 1996; 335:59-60.

26. Antman EM for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94:911-921. (CM Gibson listed in appendix as a participant of the study group)

27. Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM. Combined hypolipidemic drug therapy in normocholesterolemic patients with coronary heart disease: A stepped-care algorithm with four agents. Annals of Internal Medicine 1996; 125:529-540.

28. Dotani I, Dodge TJ, Goel M, Al-Mousa EN, McLean C, Rizzo MJ, Ryan K, Vatner R, Marble SJ, Daley WL, Gibson CM. New Techniques in the angiographic analysis of coronary flow. Journal of Interventional Cardiology 1996; 9:429-444.

29. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E and the TIMI 10A Investigators. TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A Dose-ranging Trial. Circulation, 1997; 95:351-356.

30. The TIMI 11A Investigators. Dose- ranging trial of Enoxaparin for unstable angina: Results of TIMI 11A. Journal American College of Cardiology 1997; 29:1474-1482.

31. Gibson CM, Cannon CP, Greene RM, Sequeira RF, Margorien RD, Leya F, Diver DJ, Baim DS, Braunwald E for the TIMI 4 study group. Rescue angioplasty in the TIMI 4 Trial. American Journal of Cardiology 1997; 80: 21-26.

32. Gibson CM, Marble SJ, Rizzo MJ, Moynihan J, McLean C, Ryan K, Sparano A, Piana RN, McCabe CH, Cannon CP for the TIMI 4 study group. Relationship between injections prior to 90 minute angiography and coronary patency. Results of the TIMI 4 trial. American Heart Journal 1997; 134 (3): 351-355.

33. Tanasijevic MJ, Cannon CP, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Antman EM, Braunwald E for the TIMI 10A Investigators. Myoglobin, CK-MB and Cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction. Results from TIMI 10A. American Heart Journal 1997; 134: 622-30.

34. The RESTORE Investigators. The effects of platelet glycoprotein IIb/IIIa blockade with Tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96:1445-1453.

35. Gibson CM, Dodge JT, Goel M, Al-Mousa EN, Rizzo M, McLean C, Ryan K, Sparano A, Marble SJ, Daley WL, Cannon CP, Antman EM. The PTCA guidewire velocity. A new simple method to measure absolute coronary velocity and blood flow. American Journal of Cardiology 1997; 80: 1536-1539.

36. Cannon CP. McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E for the TIMI 12 Investigators. A randomized trial of an oral platelet glycoprotein IIB/IIIa antagonist, Sibrafiban, in patients post an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998,97:340-349.

37. McCormick LS, Black DM, Waters D, Brown WV, Pitt B for the AVERT Investigators. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin versus revascularization treatments (AVERT). American Journal of Cardiology 1997; 80: 1130-1133. (CM Gibson listed in appendix as a participant of the study group)

38. Al-Mousa E, Dodge JT, Rizzo M, McLean C, Ryan K, Moynihan J, Kelley M, Marble SJ, Goel M, Daley WL, and Gibson CM: The TIMI frame count in saphenous vein grafts. American Heart Journal 1998;135:323-328.

39. Dodge JT, Nykiel M, Altman J, Hobkirk K, Brennan M, Gibson CM. Coronary artery injection technique: A quantitative in vivo investigation using modern catheters. Cardiac Catheterization and Diagnosis, 1998, 44:34-39.

40. Dodge JT, Rizzo M, Nykiel M, Altman J, Hobkirk K, Brennan M, Gibson CM. Impact of injection rate on the TIMI Frame Count. American Journal of Cardiology, 1998, 81: 1268-1270.

41. Gibson CM, Goel M, Cohen DE, Piana RN, Deckelbaum LI, Harris KE, King SB for the RESTORE Investigators. Six Month Angiographic and Clinical Outcomes following IIb/IIIa blockade with Tirofiban. J Am Coll Cardiol 1998; 32:28-34.

42. Gibson CM, Ryan K, Sparano A, Moynihan JL; Rizzo MJ; Kelley M; Marble SJ; Laham R; Simons M; McClusky TR; Dodge JT. Angiographic Methods to Assess and Classify Human Coronary Angiogenesis. American Heart Journal, 1999; 137: 169-79.

43. Dauerman HL, Higgins PJ, Baim DS, Carrozza JP, Kuntz RE, Garber GR, Shubrooks SJ, Sparano AM, Gibson CM, Cohen DJ. Debulking versus simple balloon angioplasty for the treatment of diffuse in-stent restenosis. Am J Cardiol 1998; 82:277-284.

44. Dauerman HL, Higgins PJ, Baim DS, Carrozza JP, Kuntz RE, Garber GR, Shubrooks SJ, Sparano AM, Gibson CM, Cohen DJ. Debulking versus simple balloon angioplasty for the treatment of bifurcation lesions. J Am Coll Cardiol, 1998: 1845-1852.

45. Cannon CP, Gibson CM, McCabe CH, Adgey AAJ, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Fox NL, Weaver WD, Van de Werf F, Braunwald E for the TIMI 10B Investigators. TNK-Tissue Plasminogen Activator compared with Front-loaded Alteplase in Acute Myocardial Infarction: Results of the TIMI 10B Trial. Circulation, 1998; 98:2805-14.

46. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, Cannon CP, Van de Werf F, Braunwald E. The relationship between the TIMI Frame Count and clinical outcomes after thrombolytic administration. Circulation 1999; 99:1945-1950.

47. Gibson CM, Ryan K, Sparano A, Rizzo M, Moynihan J, Kelley M, Marble SJ, Dodge JT, Antman EM for the TIMI Study Group. Methodologic Drift in the Assessment of TIMI Grade 3 Flow and its Implications with Respect to the Reporting of Angiographic Trial Results. Am Heart Journal 1999; 137: 1179-1184.

48. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AAJ, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Abciximab facilitates the rate and the extent of thrombolysis: Results of TIMI 14 trial. Circulation 1999;99:2720-2732.

49. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the Atorvastatin Versus Revascularization Treatment (AVERT) Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341-6. (CM Gibson listed in appendix as a participant of the study group)

50. Gibson CM, Cannon CP, Murphy SA, Adgey J, Schweiger MJ, Sequeira RF, Grollier G, Fox NL, Weaver D, Van de Werf F, Braunwald E. Weight adjusted dosing of TNK-tissue plasminogen activator and its relationship to angiographic outcomes in the TIMI 10B trial, Am J Cardiol 1999; 84: 976-980.

51. Tanasijevic MJ, Cannon CP, Antman EM, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Braunwald E for the TIMI 10B investigators. Myoglobin, CK-MB and Cardiac troponin – I- 60 minute ratios predict infarct related artery patency after thrombolysis for acute myocardial infarction. Results from TIMI 10B. J Am Coll Cardiol, 1999; 34:739-47.

52. Gibson CM, Ryan KA, Murphy SA, Mesley R, Marble SJ, Guigliano RP, Cannon CP, Antman EM, Braunwald E. Impaired coronary blood flow in non-culprit arteries in the setting of acute myocardial infarction. J Am Coll Cardiol, 1999; 34: 974-82.

53. Gibson CM, Murphy SA, Menown I, Sequeira RF, Greene R, Van de Werf F, Schweiger MJ, Ghali M; Frey M, Ryan KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, and Braunwald E for the TIMI Study Group. Determinants of Coronary Blood Flow Following Thrombolytic Administration. J Am Coll Cardiol 1999; 34:1403-12.

54. Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Bernink JLM, Salein D, de Luna AB, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E for the TIMI 11B Investigators. Circulation 1999; 100:1593-1601. (CM Gibson listed in appendix as a participant of the study group)

55. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van de Werf F and Braunwald E for the TIMI Study Group. The Relationship of the TIMI Myocardial Perfusion Grade to Mortality Following Thrombolytic Administration. Circulation, 2000; 101:125-130.

56. de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, Frey MJ, Van der Wieken R, Van de Werf F, and Braunwald E the TIMI 14 Investigators. Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST Elevation Myocardial Infarction: A TIMI 14 Analysis. Circulation, 2000; 101: 239-243.

57. de Lemos JA, Antman EM, Giugliano RP, McCabe CH, Murphy SA, Van de Werf F, Gibson CM, Braunwald E for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Resolution of ST-Segment Elevation Correlates with Infarct Related Artery Patency and Flow After Thrombolytic Therapy. Am J Cardiol 2000; 85:299-304.

58. Dauerman HL, Pinto DS, Ho KKL, Gibson CM, Kuntz RE, Cohen DJ, Baim DS, Carrozza JP. Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty. Cathet Cardiovasc Intervent 2000; 49: 237-243.

59. Cannon L, Senior D, Fiet F, Attubato M, Rosenberg J, O’Donnell M, Hirst J, Gibson CM. Results from the intermediate vessel atherectomy trial (IVAT). Catheterization and Cardiovascular Interventions 2000; 49:396-400.

60. Coulter SA, Cannon CP, Ault KA, Antman EM, Van de Werf F, Adgey AAJ, Gibson CM, Giugliano RP, Mascelli MA, Scherer J, Barnathan ES, Braunwald E, Kleiman NS. High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction : Results From TIMI (Thrombolysis In Myocardial Infarction) 14. Circulation 2000;101 2690-2695

61. Llevadot J, Giugliano RP, McCabe C, Cannon CP, Antman EM, Murphy S, Gibson CM for the TIMI Investigators. Mild obstruction in the culprit artery after thrombolytic administration: Characterization and insight on the degree of residual stenosis. Am J Cardiol 2000; 85:1409-1413.

62. Cannon CP, Gibson CM, Lambrew CT, Tiefenbrunn AJ, French WJ, Gore JM, Hilbe J, Sanathanan L, Weaver WD, Rogers WJ for the NRMI-2 Investigators. Relationship of Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty. JAMA 2000; 283:2941-7.

63. de Lemos JA, Antman EM, Morrow DA, Llevadot J, Giugliano RP, Coulter SA, Schuhwerk K, Arslanian S, McCabe CH, Gibson CM, Rifai N. Heart-type Fatty Acid Binding Protein as a marker of reperfusion after thrombolytic therapy. Clin Chimica Acta 2000; 298:85-97.

64. Fang JC, Kinlay S, Wexberg P, Amirzadeh A, Gibson CM, Ganz P. Use of the TIMI Frame Count for the quantitative assessment of transplant associated arteriosclerosis. Am J Cardiol. 2000 Aug 15;86(8):890-892.

65. Dotani MI, Elnicki DM, Jain AC, Gibson CM. Association between pre-operative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000 Nov 15;86(10):1128-1130.

66. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. The association between white blood cell count, epicardial blood flow, myocardial perfusion and clinical outcomes in the setting of acute MI. A TIMI 10B substudy. Circulation. 2000 Nov 7;102(19):2329-34.

67. Antman EM, Gibson CM, de Lemos JA, Giugliano RP, McCabe CH, Coussement P, Menown I, Nienaber CA, Frey MJ, Van der Wieken R, Andresen D, Scherer J, Anderson K, Van de Werf F, Braunwald E for the TIMI Investigators. Combination reperfusion therapy with abciximab and reduced dose Reteplase: Results from TIMI 14. Eur Heart J. 2000 Dec 1;21(23):1944-1953.

68. Roe MT, Giugliano RP, Harrington RA, Gibson CM, Strony J, Kitt MM, Califf RM, Braunwald E. Combination reperfusion therapy for acute myocardial infarction with eptifibatide and tenecteplase. Design and methodology of the (INTEGRILIN and tenecteplase in acute myocardial infarction) INTEGRITI trial. Heart Drug 2000;1:5-13.

69. Gibson CM, Anshelevich M, Murphy S, Luu L, Hynes C, Kliris J, Kermgard S, Otten MHC, Antman EM, Cannon CP, Braunwald E for the TIMI study group. Impact of injections during diagnostic coronary angiography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Am J Cardiol. 2000 Dec 15;86(12):1378-1379.

70. Gibson CM, Goel, M, Rizzo M, Ryan K, Marble SJ, Deckelbaum L, King S for the RESTORE Investigators. Impaired Coronary Blood Flow in Non-Culprit Arteries in the Setting of Acute Coronary Syndromes: A RESTORE substudy. Am J Cardiol. 2000 Dec 15;86(12):1375-1377.

71. Gibson CM, Murphy SA, Marble SJ, McCabe CH, Antman EM, Cannon CP, Braunwald E for the TIMI Study Group. Can we replace the 90 minute TIMI flow grades with those at 60 minutes as an endpoint in thrombolysis trials? Am J Cardiol. 2000 Dec 15;86(12):1375-1377.

72. Clow FW, Fox NL, Cannon CP, Gibson CM, Berioli S, Bluhmki E, Danays T, Braunwald E, Van de Werf F, Stump DC. A simplified, incremental dosing scheme for TNK-tPA. Am Heart J 2000, in press.

73. Direct Thrombin Inhibitor Trialists’ Collaboration. Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention. Design of a meta-analysis based on individual patient data. CM Gibson is a member of the Direct Thrombin Inhibitor Trialists’ Collaboration and is listed with all authors in the appendix. Am Heart Journal website, 2001, in press.

74. de Lemos, JA, Gibson CM, Antman EM, Murphy SA, Schuhwerk KM, Schweiger M, Coussement P, Van de Werf F, Braunwald E for the TIMI 14 Investigators. Abciximab and early adjunctive percutaneous coronary intervention enhance microvascular perfusion after thrombolysis: Observations from the TIMI 14 Trial. Am Heart Journal 2000, in press.

75. Gibson CM, Cohen D, Cohen E, Liu H, Murphy S, Marble SJ, Lorenz T, Kitt M, Tcheng JE for the ESPRIT study Group. Treatment with Eptifibatide and Coronary Flow Reserve (CFR) Following Elective Stent Placement: An ESPRIT Substudy. Am J Cardiol 2001, in press.

Proceedings of Meetings

76. Cannon CP, Gibson CM. TIMI Flow Grade and TIMI Frame Count, in The First International Thrombolytic Collegium, Prognostic Markers for the Management of Acute Myocardial Infarction, published by Medical Forum, Parsippany NJ, 1997.

77. Braunwald E, Gibson CM. New strategies in the management of acute MI: Protecting the microcirculation. Medical Education Reports, Interviews and Testimony 2000; 2: 20-21.

78. The time dependent open vasculature hypothesis. Brigham and Women’s Hospital Grand Rounds series, in press December 2000.

Review Articles

79. Gibson CM, Safian RD. Measurement of Arterial Dimensions: Review of Visual and Quantitative Angiographic Techniques. Journal of Interventional Cardiology 1991; 3:66-74.

80. Gibson CM, Safian RD. Limitations of Cineangiography: Impact of New Technologies for Image Processing and Quantitation. Trends Cardiovascular Medicine 1992; 2:156-160.

81. Gibson CM, Stone PH. How do intracoronary hemodynamics affect the natural history of coronary atherosclerosis? Choices in Cardiology 1993; 7:333-335.

82. Gibson CM, Al-Mousa EN. Newer thrombolytic agents. UpToDate in Internal Medicine 1996-1998; 3:3, CD ROM.

83. Dodge JT, Gibson CM. Thrombolysis in the elderly. UpToDate in Internal Medicine 1996-1998; 3:3, CD ROM.

84. Goel M, Rizzo MJ, McLean C, Ryan K, Dotani I, Marble SJ, Daley WL, Dodge T, Gibson CM. The Open artery Hypothesis: Past, Present and Future. Journal of Thrombosis and Thrombolysis 1998; 5:101-112.

85. Gibson CM, Sparano A. Pre Hospital Thrombolysis. UpToDate in Internal Medicine 1997-1998; version 5.3 (CD ROM).

86. Gibson CM, Moynihan J. Reocclusion Following Thrombolysis. UpToDate in Internal Medicine 1997-1998; version 5.3 (CD ROM).

87. Gibson CM. Primary angioplasty versus thrombolysis in acute myocardial infarction: Strengths and limitations. UpToDate in Internal Medicine 1998; (CD ROM).

88. Gibson CM, Moynihan JL, Al-Mousa E, Campsey M, Gandhi R, Murphy S, Mattson S, Ryan KA, Mesley R, Swanson J, Arshad MN, Marble SJ. Glycoprotein IIb/ IIIa Receptor Inhibition in Interventional Cardiology. Journal of Thrombosis and Thrombolysis1999; 7: 287-301.

89. Chang D, Gibson CM. Treatment for failed thrombolysis. UpToDate in Internal Medicine 1998; (CD ROM).

90. Gibson CM. Newer thrombolytic agents and combination therapy in acute myocardial infarction. Rev Soc Cardiol Estado de Sao Paulo 1999; 1: 831.

91. Michaels A, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol 2000; 85: 50B-60B.

92. Appleby MA, Michaels AD, Chen M, Gibson CM. The Importance of the TIMI Frame Count: Implications for Future Trials. Current Controlled Trials in Cardiovascular Medicine 2000.

93. Angeja BG, Gibson CM, Chin R, Canto J, Barron HV. Use of Reperfusion Therapies in Elderly Patients with Acute Myocardial Infarction. Submitted to Drugs and Aging.

Book Chapters

94. Gibson CM. Profiles in Coronary Artery Disease in William Grossman and Donald S. Baim, Cardiac Catheterization, Angiography and Intervention, Fifth edition, Lea and Febiger, 1995, pp.757-762.

95. Gibson CM, Stone PH, Pasternak RC, Sacks FM, for the Harvard Atherosclerosis Reversibility Project Group. Impact Upon Angiographic Disease Progression Following Step Drug Therapy in Normolipidemic Patients: Results of the Harvard Atherosclerosis Reversibility Project (HARP) in Lipid lowering therapy and progression of coronary atherosclerosis, pp.179-191, 1996 Kluwer Academic Publishers, Printed in Great Britain.

96. Gibson CM. Primary and Rescue Angioplasty in the Setting of Acute Myocardial Infarction in Randomized Trials in Cardiovascular Disease, (published as a companion to Braunwald's Heart Disease), First edition, W.B. Saunders, 1999.

97. Gibson CM, Marble SJ. Rizzo MJ, Ryan K, Goel M. Insights into flow disturbances using the TIMI Frame Count, in Management of Acute Coronary Syndromes, first edition, 1998.

98. Goel M, Sparano A, Moynihan J, Kelley M, Gibson CM. Angioplasty, Stents and New devices, in Management of Acute Coronary Syndromes, first edition, 1998.

99. Dodge JT, Cannon CP, Gibson CM. Percutaneous versus pharmacologic intervention in acute MI, in Coronary Care: Management of Acute Cardiac Problems, eds. Podrid PJ, Klein MD, Philippides GJ, 1998.

100. Gibson CM. Profiles in Coronary Artery Disease in William Grossman and Donald S. Baim, Cardiac Catheterization, Angiography and Intervention, Sixth edition, Lea and Febiger, 1999.

Invited Editorials

101. Gibson CM. Primary angioplasty versus thrombolysis. New issues in the era of glycoprotein 2b3a inhibition and stenting. Annals of Internal Medicine 1999; 130: 841-847.

102. Gibson CM. The sundial and the stopwatch. American Heart Journal, 1999; 138:614-617.

103. Gibson CM. A union in reperfusion: The concept of facilitated PCI. J Am Coll Cardiol 2000; Nov 1;36(5):1497-9.

104. Angeja B, Gibson CM. Preserved Coronary Flow Reserve in Viable Myocardium: Further Evidence for the Microvascular Hypothesis. Am Heart J 2001; in press.

Clinical Communications

105. Gibson CM. Angiographic assessment of coronary flow by the TIMI frame counting technique using the Cordis StabilizerTM marker wire, distributed by Cordis Corporation (1997).

106. Goel M, Gibson CM. References on a wide variety of topics pertaining to coronary artery blood flow and patency. Journal of Thrombosis and Thrombolysis 2000; 9:85-93.

Nonprint Material

107. How to do the TIMI Frame Count. A demonstration on the PERFUSE website at www.perfuse.org

108. How to do the TIMI Myocardial Perfusion Grade. A demonstration on the PERFUSE website at www.perfuse.org

109. TIMI frame count and TIMI myocardial perfusion grades. New methods to assess coronary reperfusion. www.chestpainonline.org, Jan 2000.

Abstracts

110. Gurney CW, Simmons EL, Gaston EO, Gibson CM, Langhofer M: Further Studies of Transient and Sustained Cycling of Erythropoiesis in Mice. Exp. Hematol. 1981; 9:56.

111. Gibson CM, Gurney CW, Simmons EL, Gaston EO: Factors Affecting Cyclic Erythropoiesis in Congenitally Anemic Mice. Exp. Hematol. 1982; 10:135.

112. Gurney CW, Gibson CM, Simmons EL, Gaston EO: An Explanation of Cyclic Erythropoiesis in W/Wv and Sl/Sld Mice Following Low Doses of 89Strontium. Exp. Hematol. 1983; 11:217.

113. Gibson CM, Stone PH, Pasternak RC, Sandor T, Sacks FM. Sample Size Requirements to Assess Atherosclerosis Regression Using Quantitative Angiography. Circulation 1990; 82, suppl. III:517.

114. Gibson CM, Stone PH, Pasternak RC, Sandor T, Rosner B, Sacks FM. The Natural History of Coronary Atherosclerosis Using Quantitative Angiography: Implications for Regression Trials. JACC 1991; 17:231A.

115. Gibson CM, Stone PH, Pasternak RC, Sandor T, Rosner B, Sacks FM. Sample Size Considerations in Atherosclerosis Regression Trials. Presented at the NIH Workshop on Stabilization and Regression of Atherosclerosis, June 20 - 21, 1991.

116. Gibson CM, Diaz L, Kandarpa K, Sacks FM, Pasternak RC, Sandor T, Feldman C, Stone PH. The Relationship of Vessel Wall Shear Stress to Atherosclerosis Progression. Circulation 1991; 84, supplement II:108.

117. Carroza J, Kuntz R, Pomerantz R, Fishman R, Mansour M, Gibson M, Senerchia C, Diver D, Safian R, Baim D. Encouraging Acute and Long-Term Angiographic and Clinical Outcome of Coronary Stenting: A Large Single Center Experience. JACC 1991; 19: 48A.

118. Marcus E, Gibson M, Gwathmey J. Results of Frame-by-Frame Curvature Difference Ventriculogram Analysis. JACC 1991; 19: 16A.

119. Gibson CM, Piana RN, Davis SF, Maher KA, Breall JA, Diver DJ, Baim DS for the TIMI 4 Study Group. Improvement in Minimum Lumen Diameter During the First Day After Thrombolysis. Circulation 1992;86:I-453.

120. Gibson CM, Cannon CP, Piana RN, Maher KA, Davis SF, Breall JA, Davis V, Diver DJ for the TIMI 4 Study Group. Relationship of Coronary Flow to Myocardial Infarction Size: Two Simple New Methods to Sub-Classify TIMI Flow Grades. Circulation 1992;86:I-453.

121. Kuntz RE, Gibson CM, Gordon PC, Diver DJ. The Advantage of Continuous Angiographic Endpoints Over Absolute Luminal Narrowing in the Analysis of Restenosis. Circulation 1992;86:I-122.

122. Gordon PC, Gibson CM, Carrozza JP, Cohen DJ, Baim DS. Quantitative Angiographic Assessment of Mechanisms for the Development and Treatment of Restenosis Following Coronary Stenting. Circulation 1992; 86:I-530.

123. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH for the HARP Study Group. The Effect on Coronary Artery Stenosis of Intensive Pharmacologic Step Therapy to Improve LDL and HDL in Patients with Normal Plasma Lipid Levels. Circulation 1992; 86:I-743.

124. Friedrich SP, Gordon PC, Leidig GA, Berger CJ, Cohen DJ, Gibson CM, Miller MJ, Fishman RF, Carrozza JP, Piana RN, Kuntz RE. Clinical Events Following New Interventional Devices Are Determined by Time-Dependent Hazards. Circulation 1992; 86:I-785.

125. Gibson CM, Rosner B, Nobuyoshi M, Senerchia C, Kuntz RE. Multiple Lesions in Individual Patients Restenose Independently. Circulation 1992; 86: I-848.

126. Gibson CM, Cannon CP, Piana RN, Breall JA, Davis SF, Maher KA, Flatley M, Davis V, Diver DJ, Baim DS. Consequences of TIMI Grade 2 vs 3 Flow at 90 Minutes Following Thrombolysis JACC 1993; 21(2A):348A.

127. Gibson CM, Rosner B, Hillger L, Fisher LD, Brown BG. A comparison of outcomes and sample sizes using lesion and patient-based analyses of coronary regression data: Results of the familial atherosclerosis treatment study (FATS). JACC 1993; 21(2A):71A.

128. Gordon PC, Kuntz RE, Friedrich SP, Piana RN, Kugelmass AD, Gibson CM, Paik GY, Cohen DJ, Carrozza JP, Baim DS. Using Clinical Outcomes to Assess New Interventional Devices. JACC 1993; 21(2A): 35A.

129. Friederich SP, Kuntz RE, Gordon PC, Leidig GA, Berger CJ, Cohen DJ, Gibson CM, Fishman RF, Carrozza JP, Baim DS. "Moderate" Restenosis has a Favorable Natural History. JACC 1993; 21(2A): 321A.

130. Kloner RA, Shook TS, Przyklenk K, Davis V, Junio L, Mathews RV, Burstein S, Gibson CM, Poole K, Cannon CP, McCabe C, Braunwald E for the TIMI 4 Investigators. Previous angina alters in hospital outcome in TIMI 4: A clinical correlate to preconditioning? Circulation 1993; 88 (2): I-49.

131. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri S, Dangoisse V, Flaker GC, Davis V, Chaitman B, Wackers FJT, Zaret BL, Gibson CM, Poole WK, Braunwald E & THE TIMI 4 INVESTIGATORS. Clinical benefit of front-loaded tPA over combination thrombolytic therapy or APSAC for acute MI: results of the TIMI 4 trial. Circulation 1993; 88 (2): I-291.

132. Gibson CM, Cannon CP, Piana RN, Flatley M, Davis V, Diver DJ, Baim DS, Braunwald E. Angiographic predictors of early reocclusion in the TIMI 4 trial. Circulation 1993; 88 (2): I-489.

133. Piana RN, Paik GY, Cohen DJ, Moscucci M, Kugelmass, Gibson CM, Baim DS. Intracoronary verapamil for "no reflow" following PTCA. Circulation 1993; 88 (2): I-587.

134. Gibson CM, Cannon CP, Piana RN, Greene RM, Sequiera RF, Margorien RD, Leya F, Davis V, Baim DS for the TIMI 4 Investigators. Rescue PTCA in the TIMI 4 trial. J Am Coll Cardiol 1994: (suppl.) 225A.

135. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC for the HARP research group. Lack of anti-atherosclerotic effect of fish oil in patients with coronary disease: A controlled quantitative coronary angiographic trial. J Am Coll Cardiol 1994 (suppl.) 264A.

136. Gibson CM, Cannon CP, Baim DS, Braunwald E. TIMI Frame Count: A New Standardization of Infarct-Related Flow Grade and Its Relationship to Clinical Outcomes in the TIMI 4 Trial. Circulation 1994; 90 (2): I-220.

137. Daley WL, Gibson CM, Cannon CP, Fortin T, Raymond L, Marble SJ, McCabe CH, Braunwald E for the TIMI 4 Study Group: Correction of the TIMI frame count for differences in artery length. Circulation 1995; 92 (8): I-719.

138. Gibson CM, Feldman C, Marble SJ, McCabe CH, Braunwald E for the TIMI 4 Study Group: Contributions of epicardial and microvascular resistances to TIMI 2 vs 3 flow. Circulation 1995; 92 (8): I-529.

139. Gibson CM, Raymond L, Fortin T, Marble SJ, McCabe CH, Daley WL for the TIMI 4 Investigators: Flow in non-culprit arteries is abnormal 90 minutes after thrombolysis. Circulation 1995; 92 (8): I-530.

140. Gibson CM, McCabe CH, Braunwald E for the TIMI 4 Study Group: Improvements in coronary flow over the first day following thrombolysis. Circulation 1995; 92 (8): I-531.

141. Gibson CM, Marble SJ, McCabe CH, Cannon CP for the TIMI 4 Study Group: Injections prior to 90 minutes following thrombolysis do not affect patency. Circulation 1995; 92 (8): I-531-532.

142. Stason WB, Berger C, Cromwell J, Marble SJ, Kondo N, Gibson CM. Variation Between Hospitals in Coronary Angiographic Interpretations in the Medicare Heart Bypass Center Demonstration. Implications for CABG Surgery Rates. JACC 1996; 27(2A): 204A.

143. Gibson CM, McCabe CH, Marble SJ, Piana RN, Cannon CP, Braunwald E for the TIMI 4 Investigators. Is Gender an Independent Predictor of Angiographic and Adverse Outcomes Following Thrombolysis? JACC 1996; 27(2A): 251A.

144. Rizzo MJ, Cannon CP, McLean C, Martin NE, Goel M, Marble SJ, Dodge T, Gibson CM. Relationship Between Timing of Vessel Opening After Thrombolysis and Flow At 90 minutes. Circulation 1996; 94(8): I-440.

145. Gibson CM, Cannon CP, Marble SJ, McCabe CH, Braunwald E. The Corrected TIMI Frame Count (CTFC) Predicts Clinical Outcomes in Acute MI. Circulation 1996; 94(8): I- 441.

146. Gibson CM, McLean C, Rizzo MJ, Martin NE, Marble SJ, Dotani I, McCabe CH, Cannon CP, Braunwald E. Use of the TIMI Frame Count to Compare Flow at 90 Min. After t-PA vs TNK Administration. Circulation 1996; 94(8): I- 89.

147. Gibson CM, Goel M, Dotani I, Rizzo MJ, McLean C, Martin NE, Al-Mousa EN, Marble SJ, Daley WL, Dodge T. The Post-PTCA TIMI Frame Count and Mortality in RESTORE. Circulation 1996; 94(8):I- 85.

148. Gibson CM, Dotani I, Goel M, McLean C, Rizzo MJ, Lis J, Martin NE, Marble SJ, Al-Mousa EN, Dodge T, Daley WL, Ross AM. Flow Improvements Following Intracoronary Stent Placement. Circulation 1996; 94(8): I- 453.

149. Goel M, Martin NE, Rizzo MJ, McLean C, Daley WL, Dodge T. Variation in Velocity Proximal and Distal to Stenoses Following Thrombolysis: Implications for Angiographic Assessment of TIMI Flow Grades. Circulation 1996; 94(8): I-441.

150. Gibson CM, Daley WL, Rizzo MJ, McLean C, Martin NE, Dotani I, Al-Mousa EN, Goel M, Marble SJ, Dodge T. Flow Following Primary PTCA For Acute MI. Circulation 1996; 94(8): I-670.

151. Tanasijevic M, Cannon CP, McCabe CH, Gibson CM, Braunwald E. Cardiac Troponin I, CK-MB and Myoglobin for Early, Noninvasive Assessment of Coronary Reperfusion After Thrombolysis for Acute Myocardial Infarction. Results from TIMI 10A. Circulation 1996; 94(8): I-322.

152. Ryan KA, Rizzo MJ, McLean C, Dotani I, Goel M, Marble SJ, Al-Mousa EN, Daley WL, Dodge T: The Relationship Between Dissection Grade & Coronary Blood Flow as well as Other Angiographic Outcomes After PTCA. JACC; 1997, 29(2): 277A.

153. Gibson CM, Rizzo MJ, McLean C, Ryan KA, Vatner R, Fortin T, Goel M, Dotani I, Daley WL, Dodge T: Flow in Culprit Arteries Following PTCA is Faster Than That in Non-culprit Arteries: Timing & Magnitude of Hyperemia. JACC; 1997, 29(2): 18A.

154. Goel M, Rizzo MJ, McLean C, Ryan KA, Dotani I, Vatner R, Marble SJ, Dodge T: Non-Culprit Artery Blood Flow in Acute Coronary Syndromes is Related to Culprit Artery Blood Flow: A RESTORE substudy. JACC;1997, 29(2): 13A.

155. Gibson CM, Dotani I, Goel M, Rizzo MJ, McLean C, Ryan KA, Marble SJ, Al-Mousa EN, Daley WL, Dodge T: The Relationship Between Thrombus & Angiographic Outcomes Before & After PTCA in Acute Coronary Syndromes. JACC; 1997, 29(2):130A.

156. Gibson CM, Rizzo MJ, McLean C, Dotani I, Goel M, Ryan KA, Marble SJ, Al-Mousa EN, Daley WL, Dodge T: The TIMI Frame Count & Restenosis: Faster is Better. JACC; 1997, 29(2): 201A.

157. Rizzo MJ, Dotani I, McLean C, Ryan KA, McCabe CH, Tanasijevic M, Cannon CP, Gibson CM, Braunwald E: Persistent Myoglobin Elevation is Associated with Slower Flow in Patent Culprit Arteries Following Successful Thrombolysis. JACC; 1997, 29(2): 132A.

158. McLean, CM, Rizzo MJ, Ryan KA, Goel M, Marble SJ, Daley WL, Dodge T, Gibson CM: Predictors of Slowed Non-Culprit Blood Flow Post Thrombolysis. JACC; 1997, 29(2): 131A.

159. Gibson CM, McLean C, Rizzo MJ, Ryan KA, Cannon CP, Braunwald E: Flow After Adjunctive & Rescue PTCA in TIMI 4 & TIMI 10. JACC; 1997, 29(2): 131A.

160. Gibson CM, Goel M, Dotani I, Rizzo MJ, Ryan KA, McLean C, Marble SJ, Al-Mousa EN, Daley WL, Dodge T: Use of the PTCA Guidewire to Measure Artery Length and the TIMI Frame Count to Measure Time as a Method of Calculating Coronary Velocity (=Length/Time) & Coronary Blood Flow). JACC; 1997, 29(2): 18A.

161. Dodge T, Goel M, Al-Mousa EN, Daley WL, Brown G, Gibson CM: In Vivo Validation of a New Three Dimensional Vector Model of distance in Human Coronary Arteries. JACC; 1997, 29(2): 35A.

162. Sparano AM, Ryan KA, McLean C, Rizzo MJ, Moynihan JL, Dodge TJ, Marble SJ, Gibson CM: Angiographic Characteristics of the 3 Epicardial Arteries in Acute MI. Intervention in Acute Coronary Syndromes Course, Allegheny University of the Health Sciences, June 1997.

163. Rizzo MJ, McLean C, Ryan KA, Moynihan JL, Sparano AM, Marble SJ, Dodge TJ, Gibson CM: Current Smokers Have Faster TIMI Frame Counts After Thrombolysis. Intervention in Acute Coronary Syndromes Course, Allegheny University of the Health Sciences, June 1997.

164. Moynihan JL, Rizzo MJ, Ryan KA, McLean C, Sparano AM, Dodge TJ, Marble SJ, Gibson CM: Comparison of Angiographically Derived Velocity to Doppler Velocity. Intervention in Acute Coronary Syndromes Course, Allegheny University of the Health Sciences, June 1997.

165. Ryan KA, Rizzo MJ, Sparano AM, McLean C, Moynihan JL, Dodge TJ, Marble SJ, Gibson CM: Angiographic Determinants of Dye Washout Following Thrombolysis. Intervention in Acute Coronary Syndromes Course, Allegheny University of the Health Sciences, June 1997.

166. Gibson CM, Marble SJ, Rizzo MJ, Ryan K, McLean C, Sparano AM, Moynihan J, Al-Mousa E, Dodge T: Pooled Analysis of Primary Stenting in Acute MI in 1,357 Patients. Circulation 1997, 96: I-340.

167. Gibson CM, Ryan K, McLean C, Moynihan J, Sparano AM, Ralston A, Rizzo MJ, Dodge T: Relationship of Pulsatile Flow to PTCA Success Following Thrombolysis. Circulation 1997, 96: I-397.

168. Gibson CM, Rizzo MJ, McLean C, Sparano AM, Ryan K, Moynihan J, Ralston A, Dodge T, Cannon CP, Braunwald E. Adjunctive Stenting Following Thrombolysis in TIMI 10A & B. Circulation 1997, 96: I-328.

169. Gibson CM, Rizzo MJ, McLean C, Ryan K, Sparano AM, Moynihan J, Al-Mousa E, Dodge T: Multivariable Model of Coronary Flow at 90 Minutes Following Thrombolysis. Circulation 1997, 96: I-648.

170. Gibson CM, Cannon CP, McCabe CH, Van de Werf F, Braunwald E: A Randomized Prospective Comparison of TPA with TNK Using the TIMI Frame Count: Results of TIMI 10B. Circulation 1997, 96: I-330.

171. Al-Mousa E, Cannon L, Senior D, Feit F, Attubato M, Rosenberg J, O=Donnell, Ryan K, Sparano AM, Gibson C: Directional Atherectomy Normalizes Guidewire Velocity in the Intermediate Vessel Atherectomy Trial (IVAT).Circulation 1997, 96: I-648.

172. Dodge T, Sparano AM, Ryan K, McLean C, Ralston A, Al-Mousa E, Daley WL: Best Angiographic Views to Minimize Coronary Artery Foreshortening. Circulation 1997, 96: I-78.

173. Rizzo MJ, Moynihan J, Ryan K, McLean C, Sparano AM, Marble SJ, Manning W: Distance from the Ostium to the Culprit Coronary Lesions: Implications for New Non-Invasive Coronary Imaging Techniques. Circulation 1997, 96: I-306.

174. Gibson CM, Rizzo MJ, McLean C, Ryan K, Sparano AM, Moynihan J, Marble SJ, Goel M, Daley WL, Piana RN: Multivariable Model of the Determinants of Flow Before and After PTCA in Acute Ischemic Syndromes. Circulation 1997, 96: I-398.

175. Cannon L, Senior D, Fiet F, Attubato M, Rosenberg J, O=Donnell M, Hirst J, Gibson CM. Preliminary results from the intermediate vessel atherectomy trial (IVAT). (1997 TCT).

176. Cannon CP, McCabe CH, Gibson CM, Adgey AJ, Schweiger MJ, Sequeira RF, Frey M, Mueller HS, McCluskey ER, Fox NL, van de Werf FJ, Braunwald E, Weaver D. TNK-tissue plasminogen activator in acute myocardial infarction: Primary results of the TIMI 10B trial. Circulation 1997, 96: I-206.

177. Dodge T, Rizzo MJ, Al-Mousa E, Nykiel M, Hobkirk K, Altmann J, Larson J, Brennan M, Gibson CM. Injection Rate Minimally Effects the TIMI Frame Count. J Am Coll Cardiol 1998; 31: 240A.

178. Gibson M, Schweiger M, Sequeira RF, Frey M, Cannon CP, Williams DO, Van de Werf F, Braunwald E for the TIMI 10B study group. Outcomes of adjunctive PTCA/stenting for TIMI Grade 2 Flow Following Thrombolysis. J Am Coll Cardiol 1998; 31: 231A.

179. Gibson CM, Sparano A, Ryan K, Rizzo M, Moynihan J, Kelley M, Marble S, dodge JT, Cannon CP, Braunwald E for the TIMI 10B Investigators. A new Angiographic Method to Calculate Coronary Velocity & Its Relationship to Clinical Outcomes after Thrombolysis. J Am Coll Cardiol 1998; 31: 12A.

180. Gibson CM, Sparano A, Ryan K, Moynihan J, Kelley M, Rizzo M, marble S, McCabe C, Dodge JT, Cannon CP for the TIMI 10B Study Group. Flow Distal and not Proximal to the Lesion is a Correlate of Clinical Outcomes after Thrombolysis. J Am Coll Cardiol 1998; 31: 492A.

181. Moynihan J, Ryan K, Sparano A, Kelley M, Rizzo M, Marble S, Cannon CP, McCabe C, Gibson CM for the TIMI 10A and 10B Study Group. The Range of QCA Velocities for TIMI Grades 2 and 3 Flow. J Am Coll Cardiol 1998; 31: 11A.

182. Kelley M, Ryan K, McLean C, Sparano A, Moynihan J, Rizzo M, Marble S, Daley W, Dodge JT, Gibson CM for the TIMI Study Group. Non-culprit Artery Blood Flow Improves Over Time When Flow Improves in the Associated Culprit Artery. J Am Coll Cardiol 1998; 31: 371A.

183. Antman EM, Giugliano RP, McCabe CH, Gibson M, Adgey AJJ, Ghali M, Coussement P, Anderson KM, Sherer J, Van de Werf F, Braunwald E for the TIMI 14 Investigators. Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of the TIMI 14 trial. J Am Coll Cardiol 1998; 31: 191A.

184. Cannon CP, Antman EM, Gibson CM, Paul SD, Braunwald E. Critical pathway for acute ST segment elevation myocardial infarction: Evaluation of the potential impact in the TIMI 9 registry. J Am Coll Cardiol 1998; 31: 192A.

185. Dauerman HL, Baim DS, Sparano AM, Gibson CM, Kuntz RE, Carrozza JP, Cohen DJ. Balloon angioplasty versus debulking for treatment of diffuse in-stent restenosis. J Am Coll Cardiol 1998; 31: 455A.

186. Scweiger MJ, Gibson M, Cannon CP, Van de Werf F, Adgey J, Grollier G, Ghali M, Porway M, Wiseman A, Braunwald E for the TIMI 10B study group. Rescue angioplasty and stenting in TIMI 10B. Society for Cardiac Angiography and Interventions, May 1998.

187. Gibson M, Rizzo MJ, Ryan KA, Kelley MB, Marble SJ, Giugliano RP, McCabe CH, Cannon CP, Van de Werf FJ, Braunwald E. Higher Weight Adjusted Doses of TNK are Associated with Improved Non-Culprit, Global & Post PTCA Flow in Addition to Improved Culprit Flow. Circulation 1998, 98: I-280.

188. Clow FW, Fox NL, Berioli S, Danays T, Bluhmki E, Modi N, Tanswell P, Stump D, Gibson CM, Van de Werf F. A simple, incremental weight-adjusted dosing scheme for TNK-tPA, a bioengineered variant of the natural tPA molecule. Circulation 1998, 98: I-280.

189. Gibson M, Ryan KA, Kelley MB, Sparano AM, Marble SJ, DeLamos J, Cannon CP. Slower Global Flow in all 3 Epicardial Arteries after Thrombolysis is Related to Adverse Outcomes. Circulation 1998, 98: I-698.

190. Gibson M, Henry TD, Sequeira R, Schweiger, Frey M, Dodge JT, Campsey M, McKendall G. Coronary Flow in Non-culprit Arteries after Thrombolysis Predicts Flow in Culprit Arteries after Adjunctive PTCA. Circulation 1998, 98: I-698.

191. Gibson M, Giugliano RP, Anderson K, Scherer JC, McCabe CH, Antman EM. Abciximab Enhances Thrombolysis: A Comparison of Abciximab Alone Versus Abciximab Plus Low Dose Thrombolytics Using the Corrected TIMI Frame Count. Circulation 1998, 98: I-559.

192. de Lemos JA, Antman EM, Giugliano RP, Coulter SA, Lambrew C, Ghali M, Gibson M. Non-culprit blood flow is an independent correlate of ECG injury patterns after thrombolytic therapy: A TIMI 14 substudy. Circulation 1998, 98: I-826.

193. Timothy D. Henry, Brian H. Annex, Michael A. Azrin, George R. McKendall, James T. Willerson, Robert C. Hendel, Frank J. Giordano, Ronald Klein, C. Michael Gibson, Daniel S. Berman, Catherine A. Luce, Edward R. McCluskey. Double Blind, Placebo Controlled Trial of Recombinant Human Vascular Endothelial Growth Factor - The VIVA Trial. J Am Coll Cardiol 1999; 33: 384A.

194. Gibson CM, Laham RJ, Giodano FJ, Henry TD, Powell J, Azrin M, Kereiakes DJ, Annex B, Miller JM, Ryan KA, McCluskey ER. Magnitude and Location of New Angiographically Apparent Coronary Collaterals Following Intravenous VEGF Administration. J Am Coll Cardiol 1999; 33: 384A.

195. Ryan KA, Rizzo M, Kelley MB, McCabe CH, Marble SJ, Canon CP, Gibson CM. Relationship Between the Presence & Duration of Chest Pain & Blood Flow at 90 Minutes Following Thrombolytic Administration. J Am Coll Cardiol 1999; 33: 375A.

196. Gibson CM, Henry TD, Sequeria R, Schweiger MJ, Frey M, Dodge JT, McKendall G , Giugliano RP, Cannon CP, Antman EM for the TIMI study Group. Left Coronary Artery Flow is Slower than Right Coronary Artery Flow Following Adjunctive PTCA after Thrombolytic Administration. J Am Coll Cardiol 1999; 33: 382A.

197. Gibson CM, Cannon CP, McCabe CH, Marble SJ, Rizzo MJ, Ryan KA, Kelley MB, Giugliano RP, Antman EM for the TIMI Study Group. Methodologic Drift in the Assessment of the TIMI Flow Grades & its Impact on Angiographic Trial Results. J Am Coll Cardiol 1999; 33: 362A.

198. Cannon CP, Rizzo MJ, Antman EM, McCabe CH, Gibson CM, Braunwald E. Validation of a Multivariate Model for Risk Stratification in Acute MI: Results from TIMI 9B. J Am Coll Cardiol 1999; 33: 396A.

199. de Lemos JA, Antman EM, Rifai N, Murphy S, Giugliano RP, Tanasijevic M, McCabe CH, Gibson CM, Braunwald E. ST segment resolution and serum myoglobin ratio predict reperfusion after thrombolytic therapy: A TIMI 14 substudy. J Am Coll Cardiol 1999; 33:391A.

200. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley RA, Marble SJ, McCabe CH, Antman EM, Braunwald E. A New Angiographic Method to Assess Myocardial Perfusion & Its Relationship to Mortality Following Thrombolytic Administration: The TIMI Myocardial Perfusion Grade. Circulation 1999; 100: I-791.

201. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley RA, Marble SJ, McCabe CH. Can We Replace 90 Minute with 60 Minute TIMI Flow Grades to Predict Outcomes After Thrombolysis? Circulation 1999; 100: I-649.

202. de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, Frey MJ, Van der Wieken R, Van de Werf F, Braunwald E. Abciximab improves both Epicardial Flow and Myocardial Reperfusion in ST Elevation Myocardial Infarction: A TIMI 14 Analysis. Circulation 1999; 100: I-649.

203. Gibson CM, de Lemos JA, Schweiger MJ, Sequeira R, Henry TD, Donohue BC, McKendall G, Mesley RA, Marble SJ, Murphy SA, Frey M. Abnormal Flow Following Stent Placement is Associated With a Higher Mortality in Acute MI. Circulation 1999; 100: I-87.

204. Henry TD, Annex BH, Azrin MA, McKendall GR, Willerson JT, Hendel RC, Giordano FJ, Klein R, Gibson CM, Berman DS, Luce CA, McCluskey ER. Final Results of the VIVA Trial of rhVEGF for Human Therapeutic Angiogenesis. Circulation 1999; 100: I-476.

205. Coussement PK, Antman EM, Giugliano RP, McCabe CH, Gibson M, Braunwald E, Van de Werf F. Comparison of Two Different Thrombolytic Regimens With and Without Abciximab (ReoProä) in ST-Elevation Acute Myocardial infarction. Observations from the TIMI 14 Trial. Circulation 1999; 100: I-650.

206. Cannon CP, Gibson M, Lambrew CT, Shoultz DA, French WJ, Gore JM, Weaver DW, Tiefenbrunn AJ. Higher Institutional Volume of Primary Angioplasty Cases Is Associated with Lower Mortality in Acute Myocardial Infarction: An Analysis of 27,080 Patients. Circulation 1999; 100: I-809.

207. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, French WJ, Gore JM, Weaver WD, Tiefenbrunn AJ for the National Registry of Myocardial Infarction (NRMI-2). Relationship of Time to Treatment and Door-to-balloon Time to Mortality in 27,080 Patients with Acute Myocardial Infarction Treated with Primary Angioplasty. Circulation 1999; 100: I-360.

208. Mesley R, Aldrich MC, Swanson JK, Murphy S, Hynes C, Saunders T, Zemble R Marble SJ, McCabe CH, Cannon CP, Gibson CM for the TIMI Study Group. Impact of nitrate administration on the TIMI frame count and TIMI flow grades in the setting of myocardial infarction. J Am Coll Cardiol 2000; 35: 397A.

209. Gibson CM, Anshelevich M, Murphy SA, Hynes C, Saunders T, Mesley RA, Zemble R, Marble SJ, McCabe CH, Cannon CP for the TIMI Study Group. Is the Diagnostic Catheterization in Acute MI Therapeutic? Rate of Opening Closed Arteries with Diagnostic Injections Following Thrombolytic Administration in TIMI 10B and 14. J Am Coll Cardiol 2000; 35: 363A.

210. Murphy SA, de Lemos J, Gibson CM, Hynes C, Saunders T, Mesley RA, Zemble R, Marble SJ, McCabe CH, Antman EM, Braunwald E. Angiographic characteristics associated with the development of q-wave myocardial infarction. J Am Coll Cardiol 2000; 35: 391A.

211. Gibson CM, Mesley RA, Saunders T, Hynes C, Murphy SA, Zemble R, Marble SJ, McCabe CH, Antman EM, Braunwald E for the TIMI Study Group. Quantitative angiographic measurement of absolute coronary blood flow & its relation to mortality in acute MI. J Am Coll Cardiol 2000; 35: 396A.

212. De Lemos JA, Gibson CM, Antman EM, Murphy SA, Giugliano RP, Morrow DA, Schuhwerk KC, McCabe CH, Braunwald E. Abciximab improves microvascular function after rescue PCI. A TIMI 14 substudy. J Am Coll Cardiol 2000; 35: 40A.

213. Peters RJG, Spickler W, Theroux P, White H, Gibson CM, Molhoek PG, Hirsch J, Weitz JI, Weaver D. Randomized comparison of Vasoflux, a novel anticoagulant and heparin as adjunctive therapy to streptokinase for acute myocardial infarction. J Am Coll Cardiol 2000; 35: 373A.

214. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, French WJ, Core JM, Weaver D, Tiefenbrunn AJ. Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in 27,080 Patients with Acute Myocardial Infarction Treated with Primary Angioplasty. Circulation 1999; 100: I-360.

215. de Lemos JA, Gibson CM, Antman EM, Morrow DA, Schuhwerk KC, McCabe CH, Braunwald E. Correlation between the TIMI Myocardial Perfusion Grade and ST Segment Resolution among Patients with Normal Epicardial Flow after Fibrinolysis. Circulation 2000: 102: II-775.

216. Gibson CM, Cohen DJ, Cohen EA, Lui H, Luu L, Hynes C, Saunders T, Kliris J, Kermgard S, Otten M. Eptifibatide Improves Coronary Flow Reserve Following Stent Placement: An ESPRIT Substudy. Circulation 2000; 102: II-336.

217. Gibson CM, Murphy SA, Marble SJ, Schuhwerk K, de Lemos J. Adjunctive Stenting is Associated with the Development of Q-Waves in Acute MI Patients: A TIMI 14 Substudy. Circulation 2000; 102: II-434.

218. Gibson CM, Murphy SA, Barron HV, Cannon CP. Relation of Epicardial Blood Flow and Myocardial Perfusion to Long term Outcomes 2 Years Following Thrombolysis in Acute MI: A TIMI 10B Substudy. Circulation 2000; 102: II-435.

219. Moliterno DJ, Antman EM, Ohman EM, Miller J, Marble SJ, Murphy SA, Ivanc TB, Schuhwerk K, Gibson CM. Concordance between Core Labs in Trial Results Using TIMI Flow Grades and Frame Counts. Circulation 2000; 102: II-590.

220. Gibson CM, de Lemos J, Murphy SA, Marble SJ, Cannon CP, Marble SJ, Antman EM, McCabe CH, Braunwald E. Combination Therapy with Abciximab Reduces Thrombus Burden in Acute MI: A TIMI 14 Substudy. Circulation 2000; 102: II-774.

221. Gibson CM, Murphy SA, Schweiger MJ, Sequeira R, Frey M, Greene R, Barron HV, Mueller HS, Henry TD, Cannon CP, McCabe CH, Braunwald E. Prospective Evaluation of the TIMI Frame Count (CTFC)/Minimum Lumen Diameter (MLD) Ratio as a Predictor of Death & Recurrent MI Following Percutaneous Coronary Intervention for Acute MI. Circulation 2000; 102: II-774.

222. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri NJ, Gibson CM, Gibbons RJ, Borzak S, Sobel BE, Gourlay SG, Barron HV for the LIMIT AMI Investigators. A monoclonal antibody to the CD18 leukocyte integrin administered in conjunction with tPA for acute myocardial infarction: the LIMIT AMI Phase II study. European Society of Cardiology, Late breaking clinical trials session, August 2000.

Abstracts Submitted by the PERFUSE Core Laboratory and TIMI Data Coordinating Center under the Direction of CM Gibson

223. Goel M, Rizzo MJ, Jamal Syed, Dodge JT, Al Mousa E, Marble SJ, Coulter S. Relationship Between Proximal versus Distal Lesion Location in Acute MI and Baseline ST-segment Changes. Circulation 1998, 98: I-79.

224. Rizzo, MJ, Ryan KA, Cannon CP, Braunwald E. Onset of Chest Pain Between 6PM & 6AM is Associated with Poorer Outcomes Following Thrombolysis. Circulation 1998, 98: I-764.

225. Rizzo MJ, Ryan KA, Kelley MB, Moynihan J, Cannon CP, Braunwald E. Earlier Time to Treatment is Associated with Improved Coronary Blood Flow in Acute MI. Circulation 1998, 98: I-698.

226. de Lemos JA, Giugliano RP, Ghali M, Lambrew C, McCabe CH, Scherer JC, Antman EM, Braunwald E. Resolution of ST-elevation correlates with infarct-artery patency after thrombolysis: A TIMI 14 substudy. Circulation 1998, 98: I-424.

227. Cannon CP, Bray PF, Ault KA, Rizzo MJ, Braunwald E. PlA2 polymorphism of the Platelet IIb/IIIa Receptor: Increased Risk of Early Recurrent Ischemic Events in Acute Coronary Syndromes, Increased platelet Aggregability, and Effective Platelet Inhibition by an oral IIb/IIIa inhibitor: Results from TIMI 12. Circulation 1998, 98: I-171.

228. Llevadot J, de Lemos JA, Swanson JK, Arshad MN, Yannetti JE, Giugliano RP. Mild Residual Stenosis Following Thrombolysis. Circulation 1999; 100: I-791.

229. Becker RC, Spencer FA, Cannon CP, Ball SP, Murphy SA, Antman EM. The Influence of Creatinine Clearance on Maximal and Steady State Factor Xa Inhibitory Capacity Following Low Molecular Weight Heparin Administration. Circulation 1999; 100:.

230. Srinivas VS, Cannon CP, Murphy SA, Tanasijevic MJ, Sokol S, Mueller HS. Prospective Use of Serum Myoglobin for the Identification of Low Risk Patients Following ST Elevation Myocardial Infarction. Circulation 1999; 100:.

231. Coulter SA, McCabe CH, de Lemos JA, Arshad MN, Marble SJ, Swanson JK, Giugliano RP. Early Angiographic Findings among Diabetes with Acute Myocardial Infarction. Circulation 1999; 100: I-640.

232. de Lemos JA, Rifai N, Morrow DA, Sharis PJ, McHale SM, Papuchis GC, Mueller HS. Elevated Baseline Myoglobin is Associated with Increased Mortality in Acute Coronary Syndromes, Even Among Patients with Normal Baseline Troponin I: A TIMI 11B Substudy. Circulation 1999; 100: I-1955.

233. de Lemos JA, Rifai N, Llevadot J, Schuhwerk KC, Ryan KA, Ghali M, Schweiger MJ. Heart-Type Fatty Acid-Binding Protein Detects Reperfusion One Hour Following Thrombolysis: A TIMI 14 Substudy. Circulation 1999; 100: I-792.

234. Schweiger MJ, Cannon CP, Murphy SA, Cook JR, Antman EM. Percutaneous Coronary Intervention for TIMI 2 or 3 Flow: the Combined TIMI 10B/TIMI 14 Experience. Circulation 2000; 102: II-753.

235. de Lemos JA, Antman EM, Murphy SA, McCabe CH, Morrow DA, Marble SJ, Guigliano RP, Braunwald E. Early Adjunctive Stenting is Associated with less ST Resolution than Early Adjunctive PTCA. Circulation 2000; 102: II-754.

236. Cooper H, Murphy SA, Antman EM, Braunwald E, et al. Relation between Time-to-pharmacological-reperfusion and the Probability of Achieving Complete ST-segment Resolution in ST Elevation Myocardial Infarction. ACC 2000, in press.

ACC 2001 Abstracts Accepted

237. Murphy SA, Kirtane AJ, Marble SJ, Schuhwerk K, de Lemos JA, Gibson CM. Impact of contrast agent type (non-ionic vs ionic) used for coronary angiography and PCI on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute MI. ACC 2000, in press.

238. Otten M, Murphy SA, Angeja B, Lim JS, Luu LL, Kermgard SR, Marble SJ, Cannon